John Tillett, MD
Urology · Denver, CONPI 1003090382
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (42.4%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 19.9%. 2025 is the largest year on record at $14,250, more than ten times the $795 reported in 2019.
Across 161 payments — averaging $129.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Urogen Pharma, Inc.$4K
- Ferring Pharmaceuticals Inc.$4K
- Boston Scientific$3K
- Pfizer$3K
- Janssen Scientific Affairs, LLC$1K
- Telix Pharmaceuticals$1K
- plus $5K from 22 others
What the payments were for
- Consulting fees$8,87342%
- Speaking & faculty fees$3,47517%
- Travel & lodging$2,96314%
- Food & beverage$4,65322%
- Education$850%
- Other$8634%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Urogen Pharma, Inc. | 14 | $4,160 |
| Ferring Pharmaceuticals Inc. | 4 | $3,793 |
| Boston Scientific | 17 | $3,271 |
| Pfizer | 9 | $2,605 |
| Janssen Scientific Affairs, LLC | 3 | $1,302 |
| Telix Pharmaceuticals | 10 | $1,208 |
| Olympus America Inc. | 1 | $863 |
| Coloplast | 5 | $663 |
| Astellas Pharma US Inc | 27 | $604 |
| Gyrus ACMI, Inc. | 1 | $600 |
| AbbVie(2 entities) | 33 | $506 |
| Johnson & Johnson | 7 | $297 |
| Dendreon Pharmaceuticals LLC | 3 | $263 |
| Bayer | 6 | $137 |
| Laborie Medical Technologies Corp. | 2 | $117 |
| Endo Pharmaceuticals Inc. | 5 | $103 |
| Intuitive Surgical | 1 | $98 |
| AstraZeneca | 1 | $71 |
| Blue Earth Diagnostics | 3 | $52 |
| Neotract Inc. | 1 | $49 |
| Sumitomo Pharma America, Inc. | 1 | $29 |
| Rochester Medical Corporation | 1 | $22 |
| Avadel Specialty Pharmaceuticals, LLC | 1 | $20 |
| Tolmar, Inc. | 1 | $18 |
| Amgen | 1 | $17 |
| Aytu Biopharma, Inc. | 1 | $17 |
| Novo Nordisk | 1 | $13 |
| RGH Enterprises LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ADSTILADRIN$3,740
- ZUSDURI$2,455
- AMS 700$1,840
- JELMYTO$1,556
- TITAN$628
- URETERO-RENO VIDEOSCOPE$600
- PROVENGE$254
- RYBREVANT$145
- CARVYKTI$145
How this compares
$20,911 in reported general payments places this provider in the 85th percentile of 225 urology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 147 | $138,729 |
| GemtesaVibegron | 20 | $15,580 |
| Methenamine Hippurate | 100 | $10,793 |
| Finasteride | 406 | $5,406 |
| Testosterone | 46 | $4,038 |
| Tamsulosin Hcl | 297 | $3,443 |
| Oxybutynin Chloride ErOxybutynin Chloride | 74 | $2,916 |
| Testosterone Cypionate | 55 | $1,980 |
| Solifenacin Succinate | 13 | $1,416 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 42 | $1,037 |
| Potassium Citrate ErPotassium Citrate | 13 | $722 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 21 | $302 |
| Oxycodone Hcl | 12 | $38 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $604 | $138,729147 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $29 | $15,58020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 225 urology providers in Colorado.
Other urology in Denver
- Lawrence KarshDenver$706K
- Elizabeth SnyderDenver$53K
- Juan MontoyaDenver$50K
- Elias HsuDenver$23K
- Milford PainterDenver$13K
- Nina CasanovaDenver$12K
- Julien DagenaisDenver$11K
- Stephen RuyleDenver$9K
- Brian SmithDenver$8K
- Richard HeppeDenver$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.